Vitamin D and skeletal health in autoimmune bullous skin diseases: A case control study

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Marzano, Angelo Valerio ^a   Trevisan, Valentina ^a   Cairoli, Elisa ^a,b   Eller Vainicher, Cristina ^b   Morelli, Valentina ^a,b   Spada, Anna ^a,b   Crosti, Carlo ^a   Chiodini, Iacopo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmune bullous skin diseases; Vertebral fractures; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; VITAMIN D;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; BONE DENSITY; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CERVICAL SPINE RADIOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PEMPHIGUS VULGARIS; SPINE FRACTURE; VITAMIN DEFICIENCY; CASE CONTROL STUDY; COMPLICATION; MIDDLE AGED; PATHOLOGY; PEMPHIGUS; VERY ELDERLY; VITAMIN D DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; BONE DENSITY; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PEMPHIGUS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84928662894     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0230-0     Document Type: Article

References (32)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
2. Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J, Tervaert JW, et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011;10:733-43.
3. Agmon-Levin N, Shoenfeld Y. Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res. 2009;301:57-64.
4. Cutolo M, Otsa K, Paolino S, Yprus M, Veldi T, Seriolo B. Vitamin D involvement in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2009;68:446-7.
5. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61-73.
6. Ruben Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014;13:477-81.
7. Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132:1998-2004.
8. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. Br Med J. 2008;9:337. a180.
9. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320-32.
10. Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest. 2005;115:825-8.
11. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (Rituximab). Dermatology. 2007;214:310-8.
12. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926-37.
13. Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503:41-53.
14. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12:976-89.
15. Marzano AV, Trevisan V, Eller-Vainicher C, Cairoli E, Marchese L, Morelli V, et al. Evidence for vitamin D deficiency and increased fractures' prevalence in autoimmune bullous skin diseases. Br J Dermatol. 2012;167:688-91.
16. EL-Komy MHM, Samir N, Shaker OG. Estimation of vitamin D levels in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2014;28:859-63.
17. Joshi N, Minz RW, Anand S, Parmar NV, Kanwar AJ. Vitamin D deficiency and lower TGF-beta/IL-17 ratio in a North Indian cohort of pemphigus vulgaris. BMC Res Notes. 2014;7:536.
18. Tukaj S, Schmidt E, Recke A, Ludwig RJ, Zillikens D, Tukaj C, et al. Vitamin D status in patients with bullous pemphigoid. Br J Dermatol. 2013;168:873-4.
19. Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I, Minisola S, et al. Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences. Osteoporos Int. 2001;12:1026-30.
20. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4:80-90.
21. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
22. Otten JV, Hashimoto T, Hertl M, Payne AS, Sitaru C. Molecular diagnosis in autoimmune skin blistering conditions. Curr Mol Med. 2014;14:69-95.
23. Marzano AV, Tedeschi A, Fanoni D, Bonanni E, Venegoni L, Berti E, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol. 2009;160:266-72.
24. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479-85.
25. Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17:4-11.
26. Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res. 2006;298:38-45.
27. Cutolo M, Paolino S, Sulli A, Smith V, Pizzorni C, Seriolo B. Vitamin D, steroid hormones, and autoimmunity. Ann N Y Acad Sci. 2014;1317:39-46.
28. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134:128-32.
29. Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol. Arch Dermatol. 2010;146:1126-31.
30. Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2012;148:307-14.
31. Eller-Vainicher C, Cairoli E, Zhukouskaya VV, Morelli V, Palmieri S, Scillitani A, et al. Prevalence of subclinical contributors to low bone mineral density and/or fragility fractures. Eur J Endocrinol. 2013;169:225-37.
32. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheum. 2012;8:379-89.